Medline International B.V. Receives WDA and GDP Certification, Strengthening Reliable and Compliant Healthcare Distribution Across Europe

Medline International B.V. has officially received its Wholesale Distribution Authorisation (WDA) and Good Distribution Practice (GDP) certification, marking an important milestone in strengthening its pharmaceutical distribution capabilities in Europe.

A Wholesale Distribution Authorization (WDA) is an European regulatory license required for companies that procure, store, and distribute medicinal products, evidencing full compliance with Good Distribution Practice (GDP) standards for quality, safety and traceability. Reinforcing our commitment to support healthcare systems, this certification supports our objective for the safe, compliant, and timely delivery of essential products to customers. 

A cross-functional achievement

This important milestone has resulted from strong collaboration across teams and countries. Colleagues from Quality Assurance and Regulatory Affairs, Supply Chain, Complaints and Vigilance Operations and Warehouse, Human Resources, IT, FI Inventory Control, Customer Service worked closely together to design and implement a compliant distribution model.

This achievement reflects Medline’s ability to bring together expertise across functions, aligning processes, governance, and operations to meet complex regulatory requirements while continuing to support customers effectively.

“We are proud to have received this official authorization and certification for the Netherlands. It complements our pharmaceutical wholesale license in Germany and underscores our ongoing commitment to reliably supporting our customers and partners.” Stanley Dorvilly, Director Regulatory Affairs Europe. “By ensuring compliant handling, traceability, and recall readiness, the certification directly supports patient safety and continuity of care.”

By embedding this pharmaceutical compliance component into our operating model, Medline strengthens its regulatory governance, process clarity, and builds a strong foundation for expanding its pharmaceutical portfolio in the future.

What this means for customers

This authorization ensures that medical kits containing medicinal active substances are distributed to the market through a fully authorized, compliant, and controlled supply chain.

Ultimately, this directly contributes to patient safety and continuity of supply, ensuring that essential products are available where and when they are needed.

Learn more about  Medline’s building blocks.